Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
JD Rubinstein, MM O'Brien - Frontiers in Immunology, 2023 - frontiersin.org
Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized
monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic …
monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic …
[HTML][HTML] Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia
E Brivio, F Bautista, CM Zwaan - Haematologica, 2024 - ncbi.nlm.nih.gov
The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival
rates exceeding 90%. The present and future challenges are to cure the remainder of …
rates exceeding 90%. The present and future challenges are to cure the remainder of …
[HTML][HTML] Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies
Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative
review of current and emerging molecular and immunotherapies - PMC Back to Top Skip to …
review of current and emerging molecular and immunotherapies - PMC Back to Top Skip to …
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia
Although complete remission rates in adults with B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) have improved over the last two decades, it is still inferior to that of the …
leukemia (BCP-ALL) have improved over the last two decades, it is still inferior to that of the …
Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's …
CW Elgarten, JC Thompson, A Angiolillo… - Pediatric blood & …, 2022 - Wiley Online Library
Infections cause substantial morbidity for children with acute lymphoblastic leukemia (ALL).
Therefore, accurate characterization of infectious adverse events (AEs) reported on clinical …
Therefore, accurate characterization of infectious adverse events (AEs) reported on clinical …
[HTML][HTML] How to use monoclonal antibody-based therapy in ALL
E Brivio, S Samarasinghe - EJC Paediatric Oncology, 2025 - Elsevier
Abstract Acute Lymphoblastic Leukemia (ALL) represents a significant challenge in
haematology, particularly due to its aggressive nature, high relapse rates in adults and …
haematology, particularly due to its aggressive nature, high relapse rates in adults and …
New Developments in the Treatment of Pediatric Acute Lymphoblastic Leukemia
H Newman, DT Teachey - Update in Pediatrics, 2024 - Springer
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, affecting
approximately 2800 children and adolescents in the United States each year (Siegel et al …
approximately 2800 children and adolescents in the United States each year (Siegel et al …
Orbital Edema Secondary to a Sphenoidal Mass as the Presenting Symptom of High-Risk Precursor B-Cell Acute Lymphoblastic Leukemia
Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood
malignancy, known to present with ocular manifestations in rare cases. Case Presentation …
malignancy, known to present with ocular manifestations in rare cases. Case Presentation …
[PDF][PDF] Anfibody-Drug Conjugates (ADCs): A Novel Treatment for Hematologic Malignancies
K Karaszewski, WW Jędrzejczak - J Oncology. 202; 2 (1) - journalononcology.org
Antibody-drug conjugates are novel agents used in the treatment of hematologic
malignancies. These drugs consist of a cytotoxin and monoclonal antibody, which enables …
malignancies. These drugs consist of a cytotoxin and monoclonal antibody, which enables …